DBTX · Decibel Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $40.33M | $25.32M |
| SG&A | $23.63M | $14.24M |
| Total Operating Expenses | $63.96M | $39.56M |
| D&A | $1.50M | $1.60M |
| Operating Income | ($63.96M) | ($39.56M) |
| Interest Expense | - | - |
| Income Tax | $240.0K | $0 |
| Net Income | ($63.01M) | ($39.34M) |
| EPS - Basic | ($2.52) | $14.84 |
| EPS - Diluted | ($2.52) | ($19.65) |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $34.61M | $36.45M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $1.06M | $4.01M |
| Current Assets | $108.03M | $164.19M |
| Total Assets | $123.37M | $184.48M |
| Current Liabilities | $22.44M | $20.54M |
| Long-term Debt | - | - |
| Total Liabilities | $41.58M | $42.79M |
| Stockholders' Equity | $81.79M | $141.69M |
| Retained Earnings | ($277.52M) | ($214.51M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($56.90M) | ($32.66M) |
| Investing Cash Flow | $55.10M | ($13.01M) |
| Financing Cash Flow | ($213.0K) | $54.85M |
| CapEx | $463.0K | $273.0K |
| Free Cash Flow | ($57.36M) | ($32.93M) |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | 0.91 | 0.84 |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -51.1% | -21.3% |
| Return on equity | -77.0% | -27.8% |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 4.81 | 7.99 |
| Quick ratio | 4.81 | 7.99 |
| Cash ratio | 1.54 | 1.78 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.51 | 1.30 |
| Liabilities / Assets | 0.34 | 0.23 |
| Efficiency | ||
| Asset turnover | - | - |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | -61.7% | - |
| Net income growth (YoY) | -60.2% | - |
| EPS growth (YoY) | 87.2% | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | -74.2% | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | -42.3% | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Decibel Therapeutics against the 5 most active filers in the same SIC group.